Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello! A thought: I moved to San Diego last year and am always on the lookout for interesting news. If you’re here, reach out! In today’s newsletter, we discuss embryonic stem cell ethics, learn of parents searching for a treatment for their son’s ultra-rare neurological disease, and more.
The need-to-know this morning
- BridgeBio sold European marketing rights to acoramidis, its treatment for a form of progressive heart disease, to the German pharma giant Bayer. Under terms of the commercial licensing deal, BridgeBio will receive $310 million from Bayer in an upfront payment and will be eligible for royalties starting in the 30% range on acoramidis sales in Europe. European regulators are reviewing the drug, with a decision expected in 2025.
Longer treatment, less MASH
That’s the simple, take-home point from Akero Therapeutics this morning. Extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect